Ahlskog JE (2023) Levodopa, homocysteine and parkinson’s disease: what’s the problem? Parkinsonism Relat Disord 109:105357. https://doi.org/10.1016/j.parkreldis.2023.105357

Article  PubMed  Google Scholar 

Alqahtani S, Kaddoumi A (2015) Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to Entacapone low bioavailability. Biopharm Drug Dispos 36(9):587–602. https://doi.org/10.1002/bdd.1986

Article  PubMed  CAS  Google Scholar 

Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, Amalia E, Arnold G, Bajenaru O, Bergmans B, Bjornara KA, Blackie J, Bode M, Bourgeois P, Bohlhalter S, Buraga I, Burkhard PR, Busson P, Calopa M, Clausen J, Danielsen EH, Defebvre L, Delvaux V, Dethy S, Dietrichs E, De Fabregues O, Gerhard R, Gusmaroli G, Hahn K, Hauptmann B, Henriksen T, Hernandez-Vara J, Jeanjean A, Kaiserova M, Kassubek J, Kimber T, Konitsiotis S, Krüger R, Kulisevsky J, Leenders J, Lundqvist C, Ory Magne F, Marano P, Milanov I, Modugno N, Misbahuddin A, Nevrly M, Panayiotis Z, Pedersen KF, Pedersen SW, Perju-Dumbrava L, Ponsen MM, Popescu BO, Rijntjes M, Puente V, Redecker C, Schrader C, Sensi M, Simu M, Spanaki C, Storch A, Storstein A, Tomantschger V, van der Linden C, van Laar T, Viallet F, Witjas T, Wolz M, Zibetti M, Van Zandijcke M (2017) Levodopa-carbidopa intestinal gel in advanced parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018

Article  PubMed  Google Scholar 

Antonini A, Odin P, Pahwa R, Aldred J, Alobaidi A, Jalundhwala YJ, Kukreja P, Bergmann L, Inguva S, Bao Y, Chaudhuri KR (2021) The long-term impact of levodopa/carbidopa intestinal gel on ‘off’-time in patients with advanced Parkinson’s disease: a systematic review. Adv Ther 38(6):2854–2890. https://doi.org/10.1007/s12325-021-01747-1

Article  PubMed  PubMed Central  Google Scholar 

Aquilonius SM, Nyholm D (2017) Development of new Levodopa treatment strategies in parkinson’s disease-from bedside to bench to bedside. Ups J Med Sci 122(2):71–77. https://doi.org/10.1080/03009734.2017.1285374

Article  PubMed  PubMed Central  Google Scholar 

Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdere P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bezard E (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in parkinson’s disease. Prog Neurobiol 132:96–168. https://doi.org/10.1016/j.pneurobio.2015.07.002

Article  PubMed  CAS  Google Scholar 

Bhidayasiri R, Garcia Ruiz PJ, Henriksen T (2016) Practical management of adverse events related to apomorphine therapy. Parkinsonism Relat Disord 33(Suppl 1):S42–S48. https://doi.org/10.1016/j.parkreldis.2016.11.017

Article  PubMed  Google Scholar 

Bialecka M, Kurzawski M, Roszmann A, Robowski P, Sitek EJ, Honczarenko K, Gorzkowska A, Budrewicz S, Mak M, Jarosz M, Golab-Janowska M, Koziorowska-Gawron E, Drozdzik M, Slawek J (2012) Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in parkinson’s disease. Pharmacogenet Genomics 22(10):716–724

Bonderup OK, Fenger-Grøn M, Wigh T, Pedersen L, Nielsen GL (2014) Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis 20(10):1702–1707. https://doi.org/10.1097/mib.0000000000000143

Article  PubMed  Google Scholar 

Bonifacio MJ, Sousa F, Soares-da-Silva P (2021) Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by Levodopa in cynomolgus monkeys. Eur J Pharmacol 892:173742. https://doi.org/10.1016/j.ejphar.2020.173742

Article  PubMed  CAS  Google Scholar 

Brannan T, Martínez-Tica J, Yahr MD (1992) Catechol-O-methyltransferase Inhibition increases striatal L-dopa and dopamine: an in vivo study in rats. Neurology 42(3 Pt 1):683–685. https://doi.org/10.1212/wnl.42.3.683

Article  PubMed  CAS  Google Scholar 

Brohée S, Roze E, Grabli D, Letrillart H, Mantisi L, Foucard C, Hainque E, Cormier F, Méneret A, Hauw F (2025) Cognitive and psychiatric adverse effects of foslevodopa/foscarbidopa in patients with Parkinson’s disease. Movement Disord Clin Pract. https://doi.org/10.1002/mdc3.70060

Buhmann C, Hilker R, Lingor P, Schrader C, Schwarz J, Wolz M, Reichmann H (2017) Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. J Neural Transm 124(8):1005–1013. https://doi.org/10.1007/s00702-017-1698-7

Article  PubMed  Google Scholar 

Calne DB, Reid JL, Vakil SD (1973) Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther 14(3):386–389. https://doi.org/10.1002/cpt1973143386

Article  PubMed  CAS  Google Scholar 

Chaudhuri KR, Kovács N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, Cubo E, Anca-Herschkovitsch M, Iansek R, Siddiqui MS, Simu M, Bergmann L, Ballina M, Kukreja P, Ladhani O, Jia J, Standaert DG (2023) Levodopa carbidopa intestinal gel in advanced parkinson’s disease: DUOGLOBE final 3-Year results. J Parkinsons Dis 13(5):769–783. https://doi.org/10.3233/jpd-225105

Article  PubMed  PubMed Central  CAS  Google Scholar 

Contin M, Martinelli P, Scaglione C, Avoni P, Albani F, Riva R, Baruzzi A (2008) The effect of Entacapone on Levodopa rate of absorption and latency to motor response in patients with Parkinson disease. Clin Neuropharmacol 31(5):267–271. https://doi.org/10.1097/WNF.0b013e31815c39aa

Article  PubMed  CAS  Google Scholar 

Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M (2011) The COMT Val158Met polymorphism affects the response to Entacapone in parkinson’s disease: a randomized crossover clinical trial. Ann Neurol 69(1):111–118. https://doi.org/10.1002/ana.22155

Article  PubMed  CAS  Google Scholar 

Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European academy of neurology/movement disorder Society - European section guideline on the treatment of parkinson’s disease: I. Invasive therapies. Eur J Neurol 29(9):2580–2595. https://doi.org/10.1111/ene.15386

Article  PubMed  Google Scholar 

Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, Tateno F, Tsuyusaki Y, Takahashi O (2012) Plasma Levodopa peak delay and impaired gastric emptying in parkinson’s disease. J Neurol Sci 319(1–2):86–88. https://doi.org/10.1016/j.jns.2012.05.010

Article  PubMed  CAS  Google Scholar 

Dorsey ER, Bloem BR (2018) The Parkinson Pandemic—a call to action. JAMA Neurol 75(1):9–10. https://doi.org/10.1001/jamaneurol.2017.3299

Article  PubMed  Google Scholar 

Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O, Bou NSG (2024) Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for parkinson’s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol 23(5):465–476. https://doi.org/10.1016/S1474-4422(24)00052-8

Article  PubMed  CAS  Google Scholar 

Ettcheto M, Oriol B, Elena S-L, Amanda C, MP R, Ester V, Jordi O, Carme A, Jaume F, Camins A (2020) The preclinical discovery and development of Opicapone for the treatment of Parkinson’s disease. Expert Opin Drug Discov 15(9):993–1003. https://doi.org/10.1080/17460441.2020.1767580

Article  PubMed  CAS  Google Scholar 

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord 30(4):500–509. https://doi.org/10.1002/mds.26123

Article  PubMed  CAS  Google Scholar 

Freire-Alvarez E, Kurča E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, Liu Y, Sánchez-Soliño O, Barbato LM (2021) Levodopa-Carbidopa intestinal gel reduces dyskinesia in Parkinson’s disease in a randomized trial. Mov Disord 36(11):2615–2623. https://doi.org/10.1002/mds.28703

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gandhi S, Zerenner T, Nodehi A, Lawton M, Marshall V, Al-Hajraf F, Grosset K, Morris H, Hu M, Ben-Shlomo Y, Grosset D (2024) Motor complications in Parkinson’s disease: results from 3343 patients followed for up to 12 years. Movement Disord Clin Pract. https://doi.org/10.1002/mdc3.14044

Gretarsdottir HM, Widman E, Johansson A, Nyholm D (2021) Personalized Medicine approach in treating Parkinson’s disease, using oral administration of Levodopa/Carbidopa microtablets in clinical practice. J Pers Med. https://doi.org/10.3390/jpm11080720

Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27(2):135–206

Article  PubMed  CAS  Google Scholar 

Habet S (2022) Clinical pharmacology of Entacapone (Comtan) from the FDA reviewer. Int J Neuropsychopharmacol 25(7):567–575. https://doi.org/10.1093/ijnp/pyac021

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkin